Format

Send to

Choose Destination
Trends Mol Med. 2016 Apr;22(4):303-316. doi: 10.1016/j.molmed.2016.02.004. Epub 2016 Mar 12.

Pulmonary Macrophages: A New Therapeutic Pathway in Fibrosing Lung Disease?

Author information

1
Inflammation, Repair and Development Section, National Heart and Lung Institute, Imperial College, London SW7 2AZ, UK. Electronic address: abyrne@imperial.ac.uk.
2
Inflammation, Repair and Development Section, National Heart and Lung Institute, Imperial College, London SW7 2AZ, UK; National Institute for Health Research (NIHR) Respiratory Biomedical Research Unit, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK.
3
Inflammation, Repair and Development Section, National Heart and Lung Institute, Imperial College, London SW7 2AZ, UK.

Abstract

Pulmonary fibrosis (PF) is a growing clinical problem which can result in breathlessness or respiratory failure and has an average life expectancy of 3 years from diagnosis. Therapeutic options for PF are limited and there is therefore a significant unmet clinical need. The recent resurgent interest in macrophage biology has led to a new understanding of lung macrophage origins, biology, and phenotypes. In this review we discuss fibrotic mechanisms and focus on the role of macrophages during fibrotic lung disease. Data from both human and murine studies are reviewed, highlighting novel macrophage-orientated biomarkers for disease diagnosis and potential targets for future anti-fibrotic therapies.

KEYWORDS:

clinical trials; idiopathic pulmonary fibrosis; innate immunity; pathogenesis; personalized medicine

PMID:
26979628
DOI:
10.1016/j.molmed.2016.02.004
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science Icon for Spiral, Imperial College Digital Repository
Loading ...
Support Center